CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,220,350 | -22.2% | 193,328 | +13.3% | 0.00% | 0.0% |
| Q2 2023 | $5,422,707 | +91.0% | 170,579 | +46.5% | 0.00% | – |
| Q1 2023 | $2,839,801 | +32.6% | 116,433 | +71.5% | 0.00% | – |
| Q4 2022 | $2,141,566 | -47.0% | 67,900 | -52.6% | 0.00% | – |
| Q3 2022 | $4,044,000 | -70.4% | 143,121 | -72.3% | 0.00% | -100.0% |
| Q2 2022 | $13,675,000 | +513.2% | 517,234 | +712.1% | 0.00% | – |
| Q1 2022 | $2,230,000 | -83.7% | 63,691 | -84.9% | 0.00% | -100.0% |
| Q4 2021 | $13,705,000 | -31.8% | 422,744 | -37.9% | 0.00% | -60.0% |
| Q3 2021 | $20,088,000 | -21.3% | 680,915 | -31.7% | 0.01% | 0.0% |
| Q2 2021 | $25,526,000 | +51.6% | 996,365 | -18.8% | 0.01% | +25.0% |
| Q1 2021 | $16,843,000 | -26.5% | 1,226,729 | -11.2% | 0.00% | -33.3% |
| Q4 2020 | $22,906,000 | – | 1,381,556 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |